

medicines
patent
pool

GREATER ACCESS

to medicines and health technologies
for those who need them

About MPP

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries (LMICs). Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.

MPP's mandate covers patented medicines for infectious diseases - HIV, TB, hepatitis C and also non-communicable diseases including cancer, cardiovascular diseases and diabetes, in addition to COVID-19 treatments and technologies.



Vision

A world in which people in need in low- and middle-income countries (LMICs) have rapid access to effective and affordable medical treatments and health technologies.



Mission

Our mission is to increase equitable access to innovative medicines and other health technologies through public health-oriented voluntary licensing and technology transfer.

The need

HIV, tuberculosis, and hepatitis C claimed 2.32 million deaths in 2022. Over 80% of people suffering from these diseases live in LMICs. But half of the population living in these countries lack regular access to essential medicines in a wide range of therapeutic areas. The right medicines, in the right formulations and at the right price, will prolong and save lives.

In 2020 out of nearly 10 million cancer-related deaths worldwide, 70% were in LMICs. Diabetes prevalence has been rising more rapidly in LMICs, and more than three-quarters of cardiovascular disease deaths take place in these countries.

Half of the population living in LMICs still lacks proper access to essential medicines and healthcare and millions of people face catastrophic health expenditures that drive them into poverty. The COVID-19 pandemic has exacerbated such inequities.

Indeed, there have been flagrant inequities in access to COVID-19 vaccines especially in Africa. Without more distributed manufacturing capacity across the world, LMICs will always remain at the back of the line in a pandemic. Not only does inequity in access to vaccines and therapeutics prolong and intensify the impact of pandemics but it also hinders global efforts to bring a pandemic under control.




Licensing for Public Health

MPP aims to improve access to medicines and health technologies, particularly in LMICs, and facilitate further innovation through non-exclusive voluntary licensing.

MPP operates as a non-profit voluntary licensing mechanism through partnerships with originator pharmaceutical companies and generic manufacturers that facilitate access and promote innovation.

MPP negotiates licences with patent holders and then sublicenses to multiple manufacturers, who develop and supply the licensed medicines, including new formulations and combinations. The treatments are made available in a defined set of LMICs, sometimes in exchange for royalties.



Key features of MPP licences

The terms and conditions in MPP licences seek to improve treatment options for the broadest number of people living in LMICs, and are negotiated on a case-by-case basis with each patent holder.



Wide geographical scope

148 countries benefitting from MPP's licences



Quality assured products

Strict quality assurance policies



Non-exclusive

To encourage generic competition



Flexibility

To adapt to circumstances and achieve public health goals



Waivers

For data exclusivity



Complementarity

To other mechanisms and tools to facilitate access to treatments



Transparency

MPP's licences are published on our website



Licence management

To monitor compliance and prevent market leakage



Our footprint – MPP's impact

Modelling the impact of public health-oriented voluntary licensing

Positively impacting peoples' lives is one of the main goals of MPP activities. MPP's impact assessment is based on country-level modelling and contrasting MPP's contribution to alternative scenarios where key WHO-recommended medicines would not have been available through MPP licences. The methodology considers the role of MPP licences in supporting expanded generic competition and supporting increased uptake, with beneficial health and economic outcomes.¹

¹ Morin S, Moak HB, Bubb-Humfries O, von Drehle C, Lazarus JV, Burrone E. The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study. *Lancet Public Health*. 2022;7(2):e169-e176. doi:10.1016/S2468-2667(21)00202-4



34.69

**billion doses
of treatment
supplied
(2010 - 2022)**

By 2030

\$3.8

**billion
projected savings**



By 2030

170,000

projected deaths averted





93.89

million patient-years
of treatment through MPP's generic
partners (2010 - 2022)



\$1.5

billion dollars

saved through
MPP's licences
(2010 - 2022)

148

countries
have benefited from
access to MPP's
products




MPP's collaborations

MPP collaborates closely with product developers and generic manufacturers through its licence management programme to ensure its licences result in the rapid distribution of quality, effective medicines at affordable prices. The organisation's current remit includes patented essential medicines with high-medical value, with a priority given to small molecules, and those with strong potential for future inclusion on the World Health Organization Model List of Essential Medicines (EML).

By the end of 2022, companies working through MPP have distributed more than 34.69 billion doses of high-quality medicines to LMICs.



MPP's current network of generic manufacturers and product developers are in 14 countries ensuring the importance of local production



57 generic manufacturers and product developers

Bangladesh
Beximco
Incepta

China
Apeloa
Aurisco
Biochem
BrightGene
Desano

Fosun
Jiuzhou
Huahai
Langhua
Lepu Pharma
Zhejiang Charioteer

Dominican Republic
Magnachem

India
Amneal
Arene
Aurobindo
Biocon
Biophore
Cadila
Cipla

Divi's
Dr Reddy's
Emcure
Eugia
Glenmark
Granules
Hetero
Laurus

Lupin
Macleods
Mangalam
Micro Labs
MSN
Natco
SMS
Pharma

Strides
Sun
Torrent
USV
Viatris
Zydus
Cadila

Indonesia
Kimia Farma

Jordan
Hikma

Kenya
UCL

Mexico
Neolpharma

Pakistan
Remington

Serbia
FHI Zdravlje

South Africa
Adcock Ingram
CPT

South Korea
Celltrion
Dongbang

Ukraine
Darnitsa
Lekhim

Vietnam
Stella

Product developers
Biotech
TB Alliance
Gates MRI

Sharing expertise

MedsPaL
THE MEDICINES PATENTS AND LICENCES DATABASE

www.medspaL.org

As part of MPP's mission to improve patent transparency, MPP created a suite of Patent Information tools and Licenses Database: MedsPaL is the world's leading tool on the patent status of essential medicines in LMICs.

MedsPal includes patent and licensing data including over 17,770 national patent applications and 70 licenses covering 151 priority medicines and 319 formulations, in 137 LMICs.

LAPaL
THE LONG-ACTING THERAPEUTICS
PATENTS AND LICENCES DATABASE

www.lapaL.ch

LAPaL provides information on selected long-acting technologies in the fields of HIV, viral hepatitis, tuberculosis, and malaria.

VaxPaL
COVID-19 VACCINES PATENT DATABASE

www.vaxpal.org

MPP's patents database VaxPAL is a free resource that provides information on the patent status of COVID-19 vaccines worldwide. By the end of 2022, the database includes 5,544 national patent applications, 96 international applications, and had searchable information on 13 vaccines in 117 countries (covering both high-income countries and LMICs).



mRNA Technology Transfer Programme

The mRNA Technology Transfer Programme was set up to address the inequalities in access to vaccines in LMICs that emerged during the COVID-19 pandemic. The objectives of the Programme are to establish and enhance sustainable mRNA vaccine manufacturing capacity and to develop skilled human capital in the regions where mRNA vaccine manufacturing capacity is established or can be enhanced.

The key principles leading the Programme activities are:

- 1** **Equitable access to mRNA technologies** suitable for pandemic response.
- 2** **Create value and share intellectual property** through open access to innovation.
- 3** **Promote sustainable capacity to produce mRNA vaccines** with coherent policies and adequate investments.



1	First Partner – Biovac	6	BioGenerica Pharma S.A.E	11	Institut Pasteur de Tunis
2	BioVax	7	Biovaccines Nigeria Limited	12	Institut Torlak
3	Bio-Manguinhos/Fiocruz	8	Darnitsa	13	National Institute of Health
4	Biofarma	9	Incepta Vaccine Ltd	14	Polyvac
5	BiologicalE	10	Institut Pasteur de Dakar	15	Sinergium Biotech

The Programme funders

The project is funded by: African Union/ African CDC, Belgium, Canada, ELMA Foundation, European Commission, France, Germany, Norway, SAMRC and South Africa.



Scan QR Code to access
the digital Annual Reports


@MedsPatentPool

www.linkedin.com/company/medicines-patent-pool/

youtube.com/user/MedicinesPatentPool

GREATER ACCESS

to medicines and health technologies
for those who need them



In Geneva:

Rue de Varembe 7, fifth floor
1202 Geneva, Switzerland
Tel. +41 (0)22 533 50 50
office@medicinespatentpool.org

In Mumbai:

Unit #1006, A wing, Kanakia Wall Street
• Chakala, Andheri-Kurla Road • Andheri (east),
Mumbai 400093 • Maharashtra, India
india@medicinespatentpool.org

MPP was founded by Unitaid, which continues to be MPP's main funder. MPP's work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP's activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.

